probenecid has been researched along with Leishmaniasis in 1 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Leishmaniasis: A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Saenz, RE | 1 |
Paz, HM | 1 |
Johnson, CM | 1 |
Marr, JJ | 1 |
Nelson, DJ | 1 |
Pattishall, KH | 1 |
Rogers, MD | 1 |
1 trial available for probenecid and Leishmaniasis
Article | Year |
---|---|
Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside.
Topics: Adult; Allopurinol; Animals; Antiprotozoal Agents; Biopsy; Clinical Trials as Topic; Drug Therapy, C | 1989 |